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This observational study was conducted to describe the risk of gastrointestinal (GI) events among patients with
atrial fibrillation (AF). We analyzed Thomson Reuters MarketScan® data from 2005 to 2009. Subjects aged ≥18 years
with ≥ 1 AF diagnosis were selected. GI events were identified from claims with a primary or secondary diagnosis
code for any GI condition. The risk of GI events was assessed using cumulative incidence (new GI events/patients
with AF without GI condition at baseline) and incidence rates (IRs), calculated as the number of patients with new
GI events divided by patient-years of observation. In addition, the CHADS2 score was evaluated at baseline to
determine the patient’s risk of stroke. A total of 557,123 AF patients were identified. The mean (median) AF patient
age was 68.2 years (70); 45% were female. The cumulative incidences of any GI event and dyspepsia were 40% and
19%, respectively. The corresponding IRs were 38.8 and 14.7 events per 100 patient–years. IRs of any GI events for
female and male patients were 43.6 and 35.5; for patients in the age groups <65, 65–74, 75–84, and ≥85 years, IRs
were 32.3, 38.9, 44.6, and 52.7; for patients with a CHADS2 score of 0, 1–2, 3–4, and 5–6, IRs were 30.3, 41.6, 56.9,
and 74.5, respectively. In this large claims database, 40% of AF patients experienced a GI event, predominantly
dyspepsia. Physicians should take age and comorbidities into consideration when managing AF patients.
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Atrial fibrillation (AF) is the most common clinical ar-
rhythmia; an estimated 2.3 million Americans were suf-
fering from this condition in 2010 (Fuster et al. 2001; Go
et al. 2001). AF is also strongly age dependent, affecting
approximately 11–12% of persons ≥80 years of age, com-
pared with only 0.1–0.2% of persons ≤55 years of age
(Go et al. 2001). AF is commonly associated with other
cardiovascular diseases, hypertension, including congest-
ive heart failure, valvular heart disease, and ischemic heart
disease (Lloyd-Jones et al. 2004). However, while literature
documenting cardiovascular comorbidities is plentiful, less
attention has been given to the prevalence and impact of
gastrointestinal (GI) conditions such as dyspepsia, gastro-
esophageal reflux disease (GERD), peptic ulcer diseases,
and GI bleeding in patients with AF (Hernandez-Diaz &
Rodriguez 2002; Locke et al. 1997; Talley et al. 1992; Talley
et al. 1995). The GI tract has been documented as one of* Correspondence: JLamori@its.jnj.com
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in any medium, provided the original work is pthe most common locations of major bleeds attributed to
a typical thromboprophylaxis regimen in stroke preven-
tion (Coleman et al. 2012).
The number of GI conditions also increases with age
(Hernandez-Diaz & Rodriguez 2002; Blachut et al. 2004;
Garcia Rodriguez et al. 1998; Som et al. 2010; Sostres
et al. 2010). Dyspepsia, for example, is a common
condition in the elderly. It is also a likely comorbidity in
patients with AF. In a recent retrospective observational
study, subjects with AF presenting with dyspepsia ten-
ded to have a greater health burden and lower quality of
life than those without dyspepsia. Moreover, these pa-
tients were at greater risk of stroke (Lamori et al. 2012).
The agents used in patients with AF to prevent stroke or
treat other comorbidities are known to increase the risk
of GI events. These agents include, but are not limited
to, anticoagulants, nonsteroidal anti-inflammatory drugs
(NSAIDs) (e.g. aspirin), corticosteroids, and calcium chan-
nel blockers (Garcia Rodriguez et al. 1998; Bytzer 2010).
Agents currently used to treat patients with GI conditionsan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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include acid secretory inhibitors, such as proton pump
inhibitors (PPIs) (Bytzer 2010; McGowan et al. 2008;
Yeomans et al. 1998).
GI conditions, in particular GERD, also have been pro-
posed as a potential independent trigger for AF, because
of the close anatomical positioning of the esophagus and
the atria, and their similar nerve innervations (i.e. vagal
nerve innervation) (Huang et al. 2012). The fact that vagal
nerve overstimulation has been observed in patients with
GERD and has been suggested as a contributing factor in
AF supports the notion of GERD-mediated AF stimula-
tion via vagal innervation. The most compelling evidence
in support of GERD-mediated AF stimulation was found
in a recent nationwide population-based survey in Taiwan,
where GERD was reported to be independently associated
with an increased risk of developing concomitant AF
(Huang et al. 2012). It is thought that the prevalence of
GERD increases with age. Whether this is the case has not
yet been fully elucidated; nevertheless, esophageal symp-
toms (i.e. severe reflux esophagitis) have been reported to
be more severe in older patients (Becher & El Serag 2011).
In the US, the management of AF is dictated by guide-
lines issued by the American College of Chest Physicians,
which use the CHADS2 classification to estimate stroke
risk. This is established by adding points relating to risk
factors of stroke – Congestive heart failure, Hypertension,
Age ≥75 years, Diabetes mellitus, prior Stroke or transient
ischemic attack or thromboembolism: a higher score
denotes a greater risk (Gage et al. 2004; Singer et al. 2008).
Oral anticoagulant therapy is recommended for patients
with a CHADS2 score ≥2, while either warfarin or aspirin
is recommended for patients with a CHADS2 score of 1
(Singer et al. 2008).
In light of the prevalence of GI comorbidities in
patients with AF and to better understand how it affects
this population, we conducted an observational study to




Health insurance claims from the Thomson Reuters
MarketScan® database were used to conduct the ana-
lysis. The MarketScan database, which combines two
separate databases (Commercial Claims and Encounters
and Medicare Supplemental and Coordination of Benefits
[COB]) to cover all age groups, contains claims from ~100
employers, health plans, and government and public
organizations representing about 30 million covered lives.
All US census regions are represented, with the South and
North Central (Midwest) regions predominating. The
MarketScan data used in the current analysis covered
the period from January 2005 through December 2009.Data used in the present study included health plan
enrollment records, patient demographics, inpatient and
outpatient medical services, and outpatient prescription
drug dispensing records. Data included in the MarketScan
database are de-identified and are in compliance with
the Health Insurance Portability and Accountability Act
(HIPAA) of 1996 to preserve patient anonymity and
confidentiality.Study design
A retrospective longitudinal cohort design was employed.
To be included in the study sample, patients were
required to meet the following criteria: (i) have at least
one primary or secondary diagnosis of AF (ICD-9-CM
code 427.31), (ii) have continuous health plan enrollment
during the study period, and (iii) be at least 18 years of age
as of the date of the index AF (index date). In addition,
patients were required to have continuous health plan
enrollment for at least 180 days prior to the index date
(baseline/washout period). The observation period of
patients spanned from the index date through the earlier
of either the health plan disenrollment date or the end of
data availability.Outcome measures
The main endpoint of the study included the risk of GI
events. These were defined as a primary or secondary
diagnosis code for any GI event (see Additional file 1 for a
complete list of ICD-9-CM codes) and the subset of GI
events based on the classification in the recent Random-
ized Evaluation of Long-Term Anticoagulation (RE-LY)
study (Connolly et al. 2009), including dyspepsia (includ-
ing upper abdominal pain, abdominal pain, and abdominal
discomfort, as well as dyspepsia), diarrhea, vomiting, and
GI bleeding.
The secondary endpoints of the study included the fol-
lowing GI conditions: constipation, intestinal diverticula,
dysphagia, esophagitis, flatulence, eructation and gas
pain, gastritis and duodenitis, GERD, malignant neo-
plasm of the digestive organs and peritoneum, nausea
alone, non-infectious gastroenteritis and colitis, other
disorders of the intestine, and peptic ulcer diseases. GI-
related hospitalization was also reported; this was defined
as a hospitalization that had any GI-related ICD-9-CM
code associated with it, either as a primary or secondary
diagnosis.
Rates of GI events were also calculated among sub-
groups with respect to gender, age (<65 years, 65–74
years, 75–84 years, and ≥85), and CHADS2 score (0,
1–2, 3–4, and 5–6). The CHADS2 score consisted of
the following stroke risk factors evaluated at baseline:
congestive heart failure, hypertension, age ≥75, diabetes,
and prior stroke or transient ischemic attack (2 points for
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for other factors) (Singer et al. 2008).
Statistical analyses
Descriptive statistics were used to describe patient base-
line characteristics. Means and standard deviations (SDs)
were used to describe continuous variables; frequencies
and percentages were reported for categorical variables.
The prevalence of GI events was calculated as the
number of patients with a GI event during the 180-day
baseline and/or study follow-up period divided by the
total number of AF patients. Cumulative incidence, cal-
culated as the number of patients with a new GI event
(i.e. post-index AF diagnosis only) divided by the total
number of AF patients without a history of GI events at
baseline, was also reported. The 95% confidence inter-
vals (CIs) of the prevalence and cumulative incidence of
GI events were computed using binomial distribution.
Finally, the incidence rates (IRs) of GI events were
calculated as the number of new GI cases divided by
patient-years of observation, which was censored at the
time of the first event. This person-time approach is
used to account for different lengths of observation
among study subjects in a non–experimental setting. IR
was expressed as number of new cases per 100 patients
per year. The 95% CIs of the IRs of GI events were
computed using the Poisson distribution. All statistical
analyses were performed using SAS version 9.2 (SAS
Institute, Inc., Cary, NC).
Results
Patient characteristics
A total of 557,123 patients with AF met the inclusion cri-
teria and formed the study population, of whom 143,955
(25.8%) had a history of GI conditions during the 180-
day baseline period. Table 1 describes the baseline charac-
teristics of the study population. The mean age (median;
SD) was 68.2 (70; 14.9) years, and 249,331 patients (44.8%)
were female. CHADS2 scores at baseline were 0, 1–2, 3–4,
and 5–6, for 165,936 (29.8%), 318,530 (57.2%), 66,436
(11.9%), and 6,221 (1.1%) patients, respectively. Comorbi-
dities at baseline included cardiovascular diseases (53.1%),
hypertension (39.3%), diabetes (20.0%), cancer (13.5%),
arthritis (12.7%), and chronic kidney disease (6.5%).
Medications that may cause GI events were taken by
359,398 (64.5%) patients with AF at baseline, the most
frequent (>10%) drug classes being antibiotics (27.6%),
opioid pain medications (24.1%), calcium channel bloc-
kers (19.3%), anticoagulants (18.9%), non-steroidal anti-
inflammatory drugs (NSAIDs; 12.1%), selective serotonin
reuptake inhibitors (SSRIs; 10.3%), and corticosteroids
(10.4%).
Medications used to treat GI events were taken by
162,016 (29.1%) patients with AF, among whom 110,762(19.9%) used PPIs, 24,122 used laxatives (4.3%), 22,720
used H-2 antagonists (4.1%), 19,550 used gastrointes-
tinal medications (3.5%), 14,165 used antiemetics (2.5%),
6,895 used antidiarrheals (1.2%), 1,198 used digestive aids
(0.2%), and 124 used antacids (0.0%).Treatment patterns
Table 2 presents the treatment patterns of medications
associated with GI conditions during the observation
period. The mean (±SD) observation period for patients
with AF was 543 ± 455 days (Table 1). During the follow-
up, 398,633 (71.6%) patients took at least one medication
that may cause GI events: anticoagulant and antiplatelet
agents were taken by 37.5% and 12.0% of patients with AF,
respectively, whereas 225,833 (40.5%) patients took at least
one medication used to treat GI events (Table 2).The
mean (±SD) exposures to medications that may cause GI
events and to medications used to treat GI events were
524 ± 453 and 393 ± 410 days, respectively (Table 2).Risk of GI events
Table 3 presents the prevalence and cumulative inci-
dence of GI events. Over the 180-day baseline and mean
follow-up of 543 days, 308,823 (55.4%) patients had at
least one GI event, 215,942 (38.8%) had at least one GI
event based on the RE-LY study classification, and 121,189
patients (21.8%) had at least one GI-related hospitali-
zation. Dyspepsia was the most common GI event, occur-
ring in 29.6% of AF patients. The other most frequent GI
events (≥5%) included intestinal diverticula (n = 62,638;
11.2%), GERD (n = 63,159; 11.3%), GI bleeding (n = 52,979;
9.5%), other disorders of the intestine (n = 49,736; 8.9%),
vomiting (n = 46,866, 8.4%), gastritis and duodenitis
(n = 46,974; 8.4%), dysphagia (n = 46,506; 8.3%), diarrhea
(n = 43,628; 7.8%), constipation (n = 35,832; 6.4%), non-
infectious gastroenteritis and colitis (n = 29,602; 5.3%),
and esophagitis (n = 28,092; 5.0%).AF patients without a history of GI conditions at baseline
For AF patients without a history of GI conditions at
baseline, the cumulative incidences of any GI event, any
GI event based on the RE-LY study classification, and
dyspepsia were 39.9%, 26.3%, and 19.1%, respectively.
The corresponding IRs were 38.8, 21.7, and 14.7 events
per 100 patient–years, respectively (Figure 1). The IRs of
any GI event for female and male patients were 43.6 and
35.5, respectively (Figure 2). The IRs of any GI event in-
creased with age and CHADS2 score: for patients in the
age groups <65, 65–74, 75–84, and ≥85 years, IRs were
32.3, 38.9, 44.6, and 52.7, respectively; for patients with a
CHADS2 score of 0, 1–2, 3–4, and 5–6, IRs were 30.3,
41.6, 56.9, and 74.5, respectively.
Table 1 Patient characteristics of the AF study population
Variable All AF patients
(N = 557,123)
AF patients without
history of GI at
baseline (N = 413,168)
Mean follow-up period,
days (SD)
543.2 (455.0) 563.3 (457.9)
Demographics
Age, years, mean (SD)
[median]
68.2 (14.9) [70] 67.7 (15) [69]
Female, n (%) 249,331 (44.8%) 177,888 (43.1%)
Region, n (%)
South 210,204 (37.7%) 155,089 (37.5%)
West 93,857 (16.8%) 71,646 (17.3%)
North Central 179,174 (32.2%) 131,464 (31.8%)
Northeast 72,331 (13.0%) 53,792 (13.0%)
Unknown 1,557 (0.3%) 1,177 (0.3%)
Type of insurance, n (%)
Comprehensive 177,702 (31.9%) 129,040 (31.2%)
EPO 1,335 (0.2%) 1,076 (0.3%)
HMO 69,097 (12.4%) 53,120 (12.9%)
POS 26,145 (4.7%) 19,932 (4.8%)
PPO 259,366 (46.6%) 192,305 (46.5%)
POS with capitation 2,308 (0.4%) 1,808 (0.4%)
CDHP 4,567 (0.8%) 3,689 (0.9%)
Other/Unknown 16,603 (3.0%) 12,198 (3.0%)
Year of index date, n (%)
2005 81,555 (14.6%) 62,282 (15.1%)
2006 105,630 (19.0%) 79,372 (19.2%)
2007 108,170 (19.4%) 80,423 (19.5%)
2008 123,788 (22.2%) 91,663 (22.2%)
2009 137,980 (24.8%) 99,428 (24.1%)
Charlson comorbidity indexa,
mean (SD)
1.36 (1.93) 1.05 (1.57)
CHADS2
a,b score, n (%)
0 165,936 (29.8%) 134,997 (32.7%)
1-2 318,530 (57.2%) 233,956 (56.6%)
3-4 66,436 (11.9%) 41,209 (10.0%)
5-6 6,221 (1.1%) 3,006 (0.7%)
History of GIa, n (%)
Any GI condition 143,955 (25.8%) 0 (0.0%)
GI events based on the
RE-LY study classificationc
87,017 (15.6%) 0 (0.0%)
Dyspepsiad 64,202 (11.5%) 0 (0.0%)
Diarrhea 12,693 (2.3%) 0 (0.0%)
Vomiting 15,448 (2.8%) 0 (0.0%)




21,373 (3.8%) 0 (0.0%)
Table 1 Patient characteristics of the AF study population
(Continued)
Diverticula of intestine 19,640 (3.5%) 0 (0.0%)
Other disorders of intestine 15,008 (2.7%) 0 (0.0%)
Gastritis and duodenitis 13,923 (2.5%) 0 (0.0%)
Dysphagia 13,306 (2.4%) 0 (0.0%)
Constipation 10,669 (1.9%) 0 (0.0%)
Noninfectious gastroenteritis
and colitis
9,166 (1.6%) 0 (0.0%)
Esophagitis 9,220 (1.7%) 0 (0.0%)




9,702 (1.7%) 0 (0.0%)
Flatulence, eructation, and
gas pain
4,868 (0.9%) 0 (0.0%)
Peptic ulcer diseases 4,352 (0.8%) 0 (0.0%)
Any GI-related hospitalization 43,851 (7.9%) 0 (0.0%)
Other comorbiditiesa, n (%)
Cardiovascular diseases 295,617 (53.1%) 202,017 (48.9%)
Chronic kidney disease 36,187 (6.5%) 20,521 (5.0%)
Diabetes 111,423 (20.0%) 76,751 (18.6%)
Hypertension 218,765 (39.3%) 148,707 (36.0%)
Arthritis 70,882 (12.7%) 47,053 (11.4%)
Any cancer 74,954 (13.5%) 42,829 (10.4%)
Baseline medicationa, n (%)
Medications that may cause
GI events
359,398 (64.5%) 257,357 (62.3%)
Anticoagulants 105,367 (18.9%) 80,059 (19.4%)
Antiplatelets 55,143 (9.9%) 37,887 (9.2%)
Corticosteroids 58,065 (10.4%) 36,247 (8.8%)
NSAIDs 67,179 (12.1%) 47,315 (11.5%)
SSRIs 57,567 (10.3%) 37,959 (9.2%)
Calcium channel blockers 107,587 (19.3%) 77,563 (18.8%)
Bisphosphonates 35,491 (6.4%) 24,934 (6.0%)
Antibiotic 154,004 (27.6%) 105,071 (25.4%)
Pain medications (opioids) 134,460 (24.1%) 84,629 (20.5%)
Antineoplastic 15,634 (2.8%) 8,978 (2.2%)
Anesthesia medication 236 (0.0%) 119 (0.0%)
Medications used to treat
poisonings
145 (0.0%) 80 (0.0%)
Iron-related medication 89 (0.0%) 44 (0.0%)
Medications used to treat
GI events
162,016 (29.1%) 91,083 (22.0%)
Antacids 124 (0.0%) 78 (0.0%)
Antidiarrheals 6,895 (1.2%) 2,592 (0.6%)
Antiemetics 14,165 (2.5%) 7,138 (1.7%)
Digestive aids 1,198 (0.2%) 429 (0.1%)
Gastrointestinal medications 19,550 (3.5%) 7,709 (1.9%)
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(Continued)
Laxatives 24,122 (4.3%) 7,893 (1.9%)
Ulcer drugs 133,053 (23.9%) 76,924 (18.6%)
Proton Pump Inhibitors 110,762 (19.9%) 62,566 (15.1%)
H-2 Antagonists 22,720 (4.1%) 14,862 (3.6%)
AF atrial fibrillation, GI gastrointestinal, EPO Exclusive Provider Organization,
HMO health maintenance organization, POS point of service, PPO preferred
provider organization, CDHP Consumer Directed Health Plans, SSRI selective
serotonin reuptake inhibitors, NSAIDs nonsteroidal anti-inflammatory drugs.
aBased on a baseline period of 180 days prior to index date.
bCHADS2 score was calculated as 1 point for congestive heart failure,
hypertension, age ≥75, and diabetes mellitus, and 2 points for prior stroke or
transient ischemic attack (Source: Gage Circulation 2004).
cIncluding dyspepsia, diarrhea, vomiting, and gastrointestinal bleeding.
dIncluding abdominal pain upper, abdominal pain, abdominal discomfort,
and dyspepsia.
Table 2 Treatment patterns of medications associated
with GI conditions
Variable All AF patients
(N = 557,123)
AF patients without
history of GI at
baseline (N = 413,168)
Medications associated with
GI, n (%)
Medications that may cause
GI eventsa
398,633 (71.6%) 298,490 (72.2%)
Medications used to treat GI
eventsb
225,833 (40.5%) 154,164 (37.3%)
Exposure to therapyc, days,
mean (SD)
Medications that may cause
GI eventsa
523.7 (452.7) 534.8 (456.5)
Medications used to treat GI
eventsb
392.6 (409.6) 383.1 (408.6)
Dispensings per patient,
mean (SD)
Medications that may cause
GI eventsa
17.6 (21.2) 17.4 (20.8)
Medications used to treat GI
eventsb
7.4 (9.3) 7.0 (8.8)
Days of supply per dispensing
per patient, mean (SD)
Medications that may cause
GI eventsa
34.7 (22.3) 35.5 (22.8)
Medications used to treat GI
eventsb
43.4 (28.6) 43.0 (29.2)
Anticoagulant and
antiplatelet agents use, n (%)
Antiplatelet 66,790 (12.0%) 48,808 (11.8%)
Anticoagulant 208,985 (37.5%) 162,597 (39.4%)
AF atrial fibrillation, GI gastrointestinal.
aIncluding anticoagulant, antiplatelet, corticosteroids, NSAIDs, SSRIs, calcium
channel blockers, bisphosponates, antibiotic, pain medications (opioids),
antineoplastic, anesthesia medication, medications used to treat poisonings,
and iron-related medication.
bIncluding antacids, antidiarrheals, antiemetics, digestive aids, gastrointestinal
agents, laxatives, and ulcer drugs.
cTime from the date of the first dispensing to the end of the days of supply
for the last dispensing.
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Our analysis of real-world data demonstrates that a large
proportion of patients with AF are at high risk of GI
events. GI events were observed in more than half of the
study population, with a prevalence of 55.4 per 100
persons. Dyspepsia was the most common GI symptom,
reported in 557,123 patients with AF (29.6%; 164,892/
557,123), accounting for 54% of all 308,823 GI events re-
ported. Dyspepsia is regarded as a significant burden for
AF patients (Lamori et al. 2012), and in several studies
of patients treated with NSAIDs and aspirin, an import-
ant reason for discontinuing treatment (CAPRIE Steering
Committee 1996; Cryer et al. 2011; Niculescu et al. 2009;
Ofman et al. 2003; Peto et al. 1988; Saini et al. 2009;
Tournoij et al. 2009). Other common GI effects inclu-
ded intestinal diverticula (62,638), GERD (63,159), and
GI bleeding (52,979). GERD was recently found to be
both a trigger for AF and associated with its develop-
ment (Huang et al. 2012).
Consistent with past studies of cardiovascular disorders
associated with AF (Carroll & Majeed 2001), our study
found cardiovascular diseases and hypertension to be
frequent at baseline. Medications that can elicit GI adverse
effects, ranging from dyspepsia to GI bleeding, include as-
pirin, other antiplatelet medications, anticoagulants, anti-
biotics, corticosteroids, SSRIs, NSAIDs, bisphosphonates,
opioids and pain medications, calcium channel blockers,
and iron-related medications, which are used to treat car-
diovascular disorders and other comorbidities (e.g. depres-
sion and arthritis) (Garcia Rodriguez et al. 1998; Sostres
et al. 2010; Bytzer 2010; Ashberg et al. 2010; Diego et al.
2011; Gabriel et al. 1991). In the current study, the most
commonly used medications reported at baseline in AF
patients, with known GI adverse effects, included pain me-
dications (opioids), antibiotics, calcium channel blockers,
and anticoagulants; 359,398 patients (64.5%) received at
least one medication that may cause GI events, and thatproportion rose to 71.6% after the index diagnosis of AF.
This finding could partly explain why, over the entire
study period, 55.4% of patients with AF had at least
one GI event. Although a large proportion of patients
presented with GI events in our study, only 40.5% of
patients with AF received treatment to counteract these
events compared to 29.1% at baseline, where 80% of
patients treated used at least one ulcer drug (i.e., PPIs
or H-2 antagonists).
In our study, we assumed that a number of patients
with AF would have received more than one medication
that could cause a GI event. The use of multiple medi-
cations by older patients reflects the multiple comor-
bidities in this population (Hajjar et al. 2007) and can
Table 3 Prevalence and cumulative incidence of GI events
Variable All patients with AF (N = 557,123) AF patients without history of GI at baseline (N = 413,168)
Number of
GI casesa
Prevalence of GI (per




(per 100 persons) [95% CIb]
Any GI event 308,823 55.4 [55.3,55.6] 164,868 39.9 [39.8,40.1]
GI events based on the RE-LY study classificationd 215,942 38.8 [38.6,38.9] 108564 26.3 [26.1,26.4]
Dyspepsiae 164,892 29.6 [29.5,29.7] 79,069 19.1 [19.0,19.3]
Gastrointestinal bleeding 52,979 9.5 [9.4,9.6] 26,067 6.3 [6.2,6.4]
Vomiting 46,866 8.4 [8.3,8.5] 20,297 4.9 [4.8,5.0]
Diarrhea 43,628 7.8 [7.8,7.9] 19,928 4.8 [4.8,4.9]
Other GI events
Diverticula of intestine 62,638 11.2 [11.2,11.3] 30,983 7.5 [7.4,7.6]
Gastroesophageal reflux disease 63,159 11.3 [11.3,11.4] 28,938 7.0 [6.9,7.1]
Other disorders of intestine 49,736 8.9 [8.9,9.0] 23,435 5.7 [5.6,5.7]
Dysphagia 46,506 8.3 [8.3,8.4] 22,071 5.3 [5.3,5.4]
Gastritis and duodenitis 46,974 8.4 [8.4,8.5] 21,422 5.2 [5.1,5.3]
Constipation 35,832 6.4 [6.4,6.5] 16,729 4.0 [4.0,4.1]
Noninfectious gastroenteritis and colitis 29,602 5.3 [5.3,5.4] 12,837 3.1 [3.1,3.2]
Esophagitis 28,092 5.0 [5.0,5.1] 11,968 2.9 [2.8,2.9]
Nausea Alone 22,673 4.1 [4.0,4.1] 9,962 2.4 [2.4,2.5]
Malignant neoplasm of digestive organs
and peritoneum
18,107 3.3 [3.2,3.3] 5,534 1.3 [1.3,1.4]
Flatulence, eructation and gas pain 17,263 3.1 [3.1,3.1] 7,209 1.7 [1.7,1.8]
Peptic ulcer diseases 13,914 2.5 [2.5,2.5] 6,311 1.5 [1.5,1.6]
Any GI-related hospitalization 121,189 21.8 [21.6,21.9] 55,744 13.5 [13.4,13.6]
AF atrial fibrillation, GI gastrointestinal.
aIncluding GI events observed during the 180-day baseline or study follow-up period.
bThe 95% confidence intervals of GI events were computed using the binomial distribution.
cIncluding GI events observed only during the study follow-up period (i.e., patients with history of GI at baseline were excluded).
dIncluding dyspepsia, diarrhea, vomiting, and gastrointestinal bleeding.















































Main endpoints Secondary endpoints
Figure 1 Incidence rate of any gastrointestinal (GI) events in atrial fibrillation patients without history of GI at baseline (N = 413,168).































Figure 2 Incidence rate of any gastrointestinal (GI) events stratified by gender, age, and CHADS2 (Congestive heart failure,
Hypertension, Age ≥75 years, Diabetes mellitus, prior Stroke or transient ischemic attack or thromboembolism) (N = 413,168).
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ample, SSRIs increase the risk of GI bleeding up to three
times and, when used concomitantly with NSAIDs, up
to 15 times (Ashberg et al. 2010). Warfarin used conco-
mitantly with aspirin, anti-infective agents, or NSAIDs,
also has been shown to increase the risk of GI bleeding
(Ashberg et al. 2010; Hallas et al. 2006; Man-Son-Hing
& Laupacis 2003; Schelleman et al. 2008; Shorr et al.
1993). Moreover, dual therapy in thromboprophylaxis
has been found to increase patients’ odds of experiencing
a major GI bleed compared with monotherapy. Admi-
nistering the antiplatelet agent clopidogrel with aspirin
increased patients’ odds of having a major GI bleed by
93% compared with aspirin monotherapy (Coleman et al.
2012). Given the greater risk for stroke with older age, we
may assume that patients in this age group are more likely
to be candidates for dual thromboprophylaxis therapy and
are therefore at greater risk for the subsequent GI effects
attributed to this regimen.
Consistent with previous findings, in our study, ad-
vancing age was found to increase the risk of GI condi-
tions, ranging from IRs of any GI event of 32.3 per 100
patient-years for patients aged <65 years to corresponding
IRs of 52.7 per 100 patient-years for patients aged ≥85
years. A higher CHADS2 score, indicative of greater
comorbidity, also was associated with a higher risk of GI
conditions, ranging from IRs of 30.3 per 100 patient-years
for a CHADS2 score of 0 to corresponding IRs of 74.5 per
100 patient-years for a CHADS2 score of 5–6. Notably,
subjects with higher CHADS2 scores tend to be older
(i.e. ≥75 years) (Oldgren et al. 2011). Given that the riskof GI events increases with age and that AF is strongly
age dependent, this study highlights the importance of
profiling the characteristics of patients with AF, in terms
of both comorbidities and age, when making treatment
decisions. We suggest that further research on GI adverse
events in AF patients, specifically regarding the potential
impact of AF therapy and age on GI conditions, is war-
ranted. Moreover, the propensity for GI conditions, such
as GERD, to trigger AF requires further elucidation. The
possible impact of GI events and other comorbidities on
the underuse of anticoagulants in AF patients also might
be explored in future research.
Our study has a number of limitations. First, claims
databases may contain inaccuracies or omissions in co-
ded procedures, diagnoses, or pharmacy claims; however,
it would be unlikely that these have significantly im-
pacted our results considering the large sample size and
the relatively high proportion of patients having a GI
event in our study. Second, antiplatelet therapy was as-
sessed based on pharmacy dispensing claims, and because
the data do not capture nonprescription medications,
such as aspirin, we may have underestimated antiplate-
let utilization. Third, some medications used to treat GI
conditions are also available without a prescription, which
may further underestimate the utilization of these agents.
In addition, the observational design was susceptible to
various biases, such as information or classification bias
(e.g. the identification of false positives of GI events). Des-
pite these limitations, well-designed observational studies
provide valuable information, with real-life scenarios and
high generalizability.
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This large population-based study of more than 500,000
patients, based on real-world data, indicates a high risk
of GI events, predominantly dyspepsia, among patients
with AF. In view of the fact that GI comorbidities
commonly coexist with AF, particularly in the elderly, it
is important to take these comorbidities into account
when managing AF.
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